But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Metsera (NASDAQ:MTSR) shareholders is whether they should be ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered class-leading Phase 1 results including ...

Investing.com -- Metsera , Inc. (NASDAQ: MTSR ), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, reported a wider-than-expected second quarter loss on Monday, ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 11 Hot New Stocks to Invest in Now. On June 22, Metsera, Inc. (NASDAQ:MTSR) presented at the 85th Scientific Sessions of the American Diabetes Association.

When InvestingPro’s Fair Value models identified Metsera Inc. (NASDAQ:MTSR) as significantly undervalued on April 1, 2025, the healthcare company’s stock was trading at $24.51. Just three and ...

Gain insights into Amneal Pharmaceuticals' Q2 2025 success, with strong growth, upgraded guidance, and promising launches like CREXONT and Brekiya.

When InvestingPro’s Fair Value models identified Metsera Inc. (NASDAQ:MTSR) as significantly undervalued on April 1, 2025, the healthcare company’s stock was trading at $24.51. Just three and a half ...

Metsera, a healthcare company focused on developing innovative treatments for obesity and metabolic disorders, had been flying under the radar despite its promising pipeline. When InvestingPro’s ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 11 Hot New Stocks to Invest in Now. On June 22, Metsera, Inc. (NASDAQ:MTSR) presented at the 85th Scientific Sessions of the American Diabetes Association.

The mean of analysts' price targets for Metsera Inc. (MTSR) points to a 55.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

For those venture-backed companies that have made their public-market debuts this year, the reception has been exceptionally ...